Krystal Biotech — Third Quarter 2026 Earnings Summary

Krystal Biotech reported third-quarter 2026 global net product revenue of $127.3 million for VYJUVEK, representing a 30% increase from the prior year, with a gross margin of 94%. The company completed pricing negotiations for VYJUVEK in Germany and Italy, with an expected launch in Italy in early 2027, while clinical data for KB113 showed regression in over 80% of basal cell carcinoma lesions in patients with Gorlin syndrome. Krystal ended the quarter with $1.2 billion in cash and investments and announced a new share repurchase program authorized for up to $400 million. The company also provided updates on its pipeline, including ongoing registrational studies for KB803 and KB801, and enrollment progress for KB407 and KB408.